Combined chemotherapy and surgery for pulmonary metastases from osteogenic sarcoma Results of 10 years experience

1988 ◽  
Vol 2 (1) ◽  
pp. 37-42 ◽  
Author(s):  
A ALJILAIHAWI ◽  
J BULLIMORE ◽  
M MOTT ◽  
J WISHEART
1983 ◽  
Vol 36 (5) ◽  
pp. 516-523 ◽  
Author(s):  
Joe B. Putnam ◽  
Jack A. Roth ◽  
Margaret N. Wesley ◽  
Michael R. Johnston ◽  
Steven A. Rosenberg

Thorax ◽  
1991 ◽  
Vol 46 (10) ◽  
pp. 727-731 ◽  
Author(s):  
S R Carter ◽  
R J Grimer ◽  
R S Sneath ◽  
H R Matthews

1983 ◽  
Vol 1 (4) ◽  
pp. 251-254 ◽  
Author(s):  
N Jaffe ◽  
E Smith ◽  
H T Abelson ◽  
E Frei

The number and time to appearance of pulmonary metastases were evaluated in 15 patients with osteogenic sarcoma receiving adjuvant chemotherapy with high-dose methotrexate and doxorubicin (adjuvant group). The results were compared to 33 age- and sex-matched controls (control group). The adjuvant group demonstrated a reduction in the number and a delay in the appearance of the metastases. The median time to development of metastases was 17 mo in the adjuvant group and 7 mo in the control group, and the median number of metastases was 2 and 12, respectively.


1984 ◽  
Vol 2 (5) ◽  
pp. 425-431 ◽  
Author(s):  
A M Goorin ◽  
M J Delorey ◽  
E E Lack ◽  
R D Gelber ◽  
K Price ◽  
...  

Between 1972 and 1981, 93 patients with extremity osteogenic sarcoma without detectable metastatic disease were treated with surgery and adjuvant chemotherapy. Fifty-two patients remain continuously free of disease. Thirty-two of the 41 patients who relapsed had pulmonary metastases only and 26 underwent thoracotomy to remove all metastatic disease. Complete resection was possible in 11 of 26 patients as defined by the removal of all macroscopic disease, no microscopic disease at resection margins, and no histologic evidence of pleural disruption by tumor. Nine of 11 patients are currently free of disease with a median duration of most recent remission of 42 months (range, 3-72 months). Four of these nine patients have had only one relapse. Only two of 15 patients with incomplete resection of metastatic disease defined by the above criteria are currently free of disease for 57 and 101 months. A significant difference in survival from initial relapse for patients made surgically free of disease using this stringent criteria was observed even when the result is stratified for time to first relapse and number of pulmonary nodules (p = 0.005). A subgroup of patients within the group undergoing thoracotomies who can be expected to have an improved survival has been defined.


2016 ◽  
Vol 5 (5) ◽  
pp. 483 ◽  
Author(s):  
Ashok Kuwal ◽  
Naveen Dutt ◽  
NishantKumar Chauhan ◽  
Puneet Pareek ◽  
LokeshKumar Saini ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document